trademan1
Long

TPIV CEO presenting at Goldman Sachs Forum

OTC_DLY:TPIV   TAPIMMUNE INC
Dr             . Glynn Wilson the Chairman and CEO             of TapImmune will present at the Sachs Associates' 3rd Annual Bio Partnering & Investment Forum on 2/23. The company had Phase I trials completed with 20 of 21 cancer patients reacting with positive immune responses. Additionally, TapImmune has a very deep drug pipeline in multipe indications for upcoming Phase II trials. Increased awareness of excellent results should promote further investment confidence and result in increases on the stock chart. We already see this happening right now.
Ideas Scripts Chart
United States
United Kingdom
India
España
France
Italia
Brasil
Россия
Türkiye
日本
한국
Home Stock Screener Forex Signal Finder Economic Calendar How It Works Chart Features House Rules Moderators For the WEB Widgets Stock Charting Library Priority Support Feature Request Blog & News FAQ Help & Wiki Twitter
Private Messages Chat Ideas Published Followers Following Priority Support Public Profile Profile Settings Account and Billing Sign Out